01
Actor registration
Economic-operator registration and SRN logic.
EUD–02 · EUDAMED question analysis
EUDAMED and Pharma: the boundary questions that may matter before compliance work begins.
EUDAMED is not a pharma database. That is precisely why pharmaceutical teams should pay attention where portfolios touch medical devices, IVDs, companion diagnostics, digital applications, substance-based devices or drug-device boundaries.
FILE 01 · Regulatory trigger
What changes on 28 May 2026.
The European Commission states that the first four EUDAMED modules become mandatory from 28 May 2026: Actor registration, UDI/Devices registration, Notified Bodies and Certificates, and Market Surveillance.
The strategic relevance is not limited to registration. Once actors, devices, certificates and market-surveillance activity move into a more structured European information environment, R&D, regulatory, quality and commercial teams need better questions than a checklist normally provides.
02
UDI/Devices
Device data, Basic UDI-DI and registration visibility.
03
NBs & Certificates
Notified-body and certificate information.
04
Market Surveillance
Regulatory visibility beyond initial registration.
Official source basis: European Commission EUDAMED overview and module pages, including the notice that the first four modules become mandatory from 28 May 2026. See European Commission EUDAMED overview, mandatory use notice, Actor module, and UDI/Devices module.
FILE 02 · Boundary logic
The relevant pharma question is not whether EUDAMED is a pharma system.
The useful question is: where does a pharma portfolio enter a medical-device, IVD or digital-health information environment without the business treating that exposure as strategically relevant?
For pharma-adjacent teams, the risk is often not ignorance of a deadline. It is category language that hides boundary exposure. A project may be discussed internally as therapy, support, diagnostics, adherence, delivery, companion logic, data capture or patient-facing software while another regulatory vocabulary is already becoming more relevant.
FILE 03 · Commercial visibility
EUDAMED can turn administrative data into a competitive reading surface.
Device records, certificates, actors and surveillance patterns can affect how competitors, partners, regulators and customers read a category.
The question for pharma is not only what data must be entered. It is what the existence, absence, timing, structure or interpretation of that data may reveal about a product strategy. That is where a Non-Consensus Question Analysis can help: before the team narrows the matter to compliance mechanics.
FILE 04 · R&D decision frame
The most expensive question may be the one no department owns.
Pharma-adjacent device exposure often lives between functions: Medical, Regulatory, Digital, R&D, Quality, Business Development and Legal.
When responsibility is distributed, the unasked questions are rarely dramatic. They are usually precise, quiet and expensive: a claim boundary, a data-field implication, a device relationship, a companion diagnostic dependency, a surveillance signal or a registration assumption that no one has made explicit.
FILE 05 · Non-Consensus questions
Questions that may deserve escalation before execution starts.
- Which products in our pipeline sit closer to MDR or IVDR exposure than our internal labels suggest?
- Which digital, diagnostic or adherence-related assets may create device-adjacent visibility under EUDAMED logic?
- Which companion-diagnostic relationships should be re-questioned before they are treated as settled?
- Which substance-based device assumptions are carried by habit rather than by explicit reasoning?
- Which drug-device boundary questions are not owned by any single internal function?
- Which registration or certificate data could indirectly signal product strategy to competitors?
- Which partner, supplier or notified-body dependencies become more legible through structured data?
- Which product claims could become more exposed when adjacent device information is easier to interpret?
- Which R&D choices become more attractive because competitors will over-focus on compliance execution?
- Which commercial opportunities appear if EUDAMED is read as market intelligence rather than only as obligation?
- Which internal vocabulary hides a device-relevant question because the portfolio is culturally treated as pharma?
- Which board-level question should be asked before the matter becomes a regulatory project plan?
FILE 06 · Buying triggers
When the €1,970 analysis makes commercial sense.
Combination exposure exists
A pharma product, delivery mechanism, software layer, diagnostic dependency or device component sits near the boundary.
No single owner is obvious
The topic moves between Regulatory, R&D, Digital, Legal, Quality and Commercial without a dedicated question owner.
Portfolio language feels too comfortable
The internal name for the product may hide a regulatory or data-visibility exposure.
A small analysis can prevent a large blind spot
The fixed €1,970 analysis is useful when one unasked boundary question could redirect attention.
This analysis does not constitute legal, regulatory or notified-body advice. It is a structured question analysis for R&D, strategy, product and regulatory-facing teams.
Single fixed fee
€1,970net · plus VAT where applicable
A document that can pay for itself with one redirected research direction.
- Immediate Stripe checkout
- 10-page structured PDF deliverable
- 10–15 Non-Consensus questions, derived & classified
- Clustering by technical and economic leverage
- Prioritisation by differentiation potential
- Zoom briefing & one revision round
FILE 08 · FAQ
Before you commission the EUDAMED analysis.
Q.01Does EUDAMED directly regulate pharma products?+
EUDAMED is built for medical devices and IVDs, not as a general pharma database. Pharma relevance appears where products, diagnostics, devices, apps or data layers touch MDR or IVDR territory.
Q.02Is this suitable for large pharma?+
Yes, when the issue is not generic education but boundary exposure, portfolio assumptions, product strategy or a high-value R&D question set.
Q.03Is this legal advice?+
No. It is a strategic Non-Consensus Question Analysis, not legal, regulatory or notified-body advice.
Q.04What is the output?+
A 10-page structured PDF with 10 to 15 questions, derivation, clustering and prioritisation by differentiation potential.
Q.05Why commission it before internal compliance work?+
Because once execution begins, the team may stop asking whether the frame itself is too narrow.
Pay now. The questions take it from there.
Immediate Stripe checkout for the fixed-fee analysis. After payment, the Zoom briefing defines the dimension set. Delivery follows within 3–5 business days from the Zoom briefing.